- Home
- DIT vs IFRX Comparison
DIT vs IFRX Comparison
Compare DIT & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIT
- IFRX
- Stock Information
- Founded
- DIT 1981
- IFRX 2007
- Country
- DIT United States
- IFRX Germany
- Employees
- DIT N/A
- IFRX N/A
- Industry
- DIT Food Distributors
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- DIT Consumer Discretionary
- IFRX Health Care
- Exchange
- DIT Nasdaq
- IFRX Nasdaq
- Market Cap
- DIT 75.2M
- IFRX 86.0M
- IPO Year
- DIT 1995
- IFRX 2017
- Fundamental
- Price
- DIT $115.00
- IFRX $1.17
- Analyst Decision
- DIT
- IFRX Strong Buy
- Analyst Count
- DIT 0
- IFRX 5
- Target Price
- DIT N/A
- IFRX $9.80
- AVG Volume (30 Days)
- DIT 314.0
- IFRX 7.7M
- Earning Date
- DIT 11-07-2025
- IFRX 11-10-2025
- Dividend Yield
- DIT 0.88%
- IFRX N/A
- EPS Growth
- DIT N/A
- IFRX N/A
- EPS
- DIT 0.92
- IFRX N/A
- Revenue
- DIT $2,254,788,287.00
- IFRX $73,729.00
- Revenue This Year
- DIT N/A
- IFRX N/A
- Revenue Next Year
- DIT N/A
- IFRX $1,216.24
- P/E Ratio
- DIT $125.00
- IFRX N/A
- Revenue Growth
- DIT 5.29
- IFRX N/A
- 52 Week Low
- DIT $94.92
- IFRX $0.71
- 52 Week High
- DIT $163.75
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- DIT 45.45
- IFRX 44.93
- Support Level
- DIT $116.54
- IFRX $1.10
- Resistance Level
- DIT $117.45
- IFRX $1.31
- Average True Range (ATR)
- DIT 0.99
- IFRX 0.19
- MACD
- DIT -0.08
- IFRX -0.03
- Stochastic Oscillator
- DIT 21.26
- IFRX 10.71
About DIT AMCON Distributing Company
Amcon Distributing Co is engaged in the wholesale and retail distribution of consumer products such as cigarettes, tobacco, confectionery, health food, and others. It operates in two segments: Wholesale distribution segment distributing consumer products to the retail outlets including convenience stores, grocery stores, liquor stores, drug stores and tobacco shops in the Central, Rocky Mountain, and Southern regions of the United States; and the Retail health food segment is a specialty retailer of natural/organic groceries and dietary supplements throughout the Midwest and Florida. The company earns a majority of the revenue from the Wholesale distribution segment.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.